The December 2019 issue of Nature magazine describes the unique potential of the BERG platform in combining patient biology & artificial intelligence for drug and clinical development, highlights its use in the development of BPM 31510 in oncology.

Hunting for New Drugs with AI

The pharmaceutical industry is in a drug-discovery slump. How much can AI help?

By David H. Freedman

THERE ARE MANY REASONS that promising drugs wash out during pharmaceutical development, and one of them is cytochrome P450. A set of enzymes mostly produced in the liver, CYP450, as it is commonly called, is involved in breaking down chemicals and preventing them from building up to dangerous levels in the bloodstream. Many experimental drugs, it turns out, inhibit the production of CYP450—a vexing side effect that can render such a drug toxic in humans…

Read the full article here.